Characteristics and outcomes of low-grade and high-grade pancreatic immune-related adverse events at a single center
Journal of Oncology Pharmacy Practice
Published online on June 11, 2025
Abstract
Journal of Oncology Pharmacy Practice, Ahead of Print.
ObjectiveImmune checkpoint inhibitors (ICIs) are widely utilized in treating various malignancies but are associated with immune-related adverse events (irAEs), which often poses challenges to their use. Pancreatic irAEs, though rare, can present as new-...
ObjectiveImmune checkpoint inhibitors (ICIs) are widely utilized in treating various malignancies but are associated with immune-related adverse events (irAEs), which often poses challenges to their use. Pancreatic irAEs, though rare, can present as new-...